

BIOMARIN PHARMACEUTICAL INC  
Form 4  
December 27, 2013

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

(Last) (First) (Middle)  
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
12/24/2013

NOVATO, CA 94949  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |   |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |   |   |
|                                 |                                      |  |                                | Code  | V   | Amount   |  |   |   |
| Common Stock                    | 12/24/2013 <sup>(1)</sup>            | 12/24/2013   | A                              | 10,000  | A   | \$ 12.99   | 60,740                                     | I | Shares Held in Bienaime Family Trust <sup>(2)</sup> |
| Common Stock                    | 12/24/2013 <sup>(1)</sup>            | 12/24/2013   | S                              | 10,000  | D   | \$ 68.7143 <sup>(3)</sup>                                | 50,740                                     | I | Shares held by Bienaime Family Trust <sup>(2)</sup> |
|                                 |                                      |  |                                |   |   |  | 10,000                                     | I |   |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

|              |  |  |        |   |  |  |
|--------------|--|--|--------|---|--|--|
| Common Stock |  |  |        |   |  | Held in irrevocable trust for Guillaume Bienaime <sup>(4)</sup>                        |
| Common Stock |  |  | 10,000 | I |  | Held in irrevocable trust for Pierre Bienaime <sup>(4)</sup>                           |
| Common Stock |  |  | 10,000 | I |  | Held in irrevocable trust for Paul Bienaime <sup>(4)</sup>                             |
| Common Stock |  |  | 10,000 | I |  | Held in irrevocable trust for Marc Bienaime <sup>(4)</sup>                             |
| Common Stock |  |  | 20,000 | I |  | Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko <sup>(4)</sup> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|--|--|---|
|--|--|--------------------------------------|--|--------------------------------|--|--|---|

and 5)

|  | Code     | V          | (A)        | (D) | Date Exercisable | Expiration Date           | Title      | Amount or Number of Shares |
|--|----------|------------|------------|-----|------------------|---------------------------|------------|----------------------------|
| Stock Option (right to buy Common Stock) | \$ 12.99 | 12/24/2013 | 12/24/2013 | M   | 10,000           | 11/11/2006 <sup>(5)</sup> | 05/10/2016 | Common Stock 10,000        |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| BIENAIME JEAN JACQUES<br>C/O BIOMARIN PHARMACEUTICAL INC.<br>105 DIGITAL DRIVE<br>NOVATO, CA 94949 | X             |           | Chief Executive Officer |       |

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact  
Date: 12/27/2013

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 plan executed on May 1, 2013.
- (2) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
- (3) The price in column 4 is a weighted average price. The price actually received ranged from \$68.29 to \$69.10. The reporting person will provide to the issuer, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) The reporting person's spouse is trustee of each child's trust.
- (5) Original option grant vests 6/48th on November 11, 2006, and 1/48th on the 11th day of every month thereafter.
- (6) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.